“…9,14 Interim data from a Phase II study in 70 patients with METex14 skipping NSCLC have been reported (Table 1; NCT02897479). 32 Patients received 600 mg or 400 mg savolitinib once daily in 21-day cycles; median duration of treatment was 6.9 months (interquartile range, 2.2 to 13.8) or 6.5 months (2.7 to 10.5), respectively; for 600 mg, three dose reductions were allowed (400 mg, then 300 mg, then 200 mg, all once daily) and for 400 mg, two dose reductions were allowed (300 mg then 200 mg, both once daily). For the 70 patients in the full analysis set, median age was 69 years (range: 65 to 75), 59% were male, 60% had never smoked, 83% had an ECOG-PS of ≥ 1, 57% had adenocarcinoma, whilst 36% had pulmonary sarcomatoid carcinoma, and 21% had brain metastases at baseline.…”